| |
|
|
|
Oxford International, Orlando, USA
2006-13-11
In keeping with Oxford International’s highly successful drug discovery series, an expert panel of speakers will present a full conference programme of over 15 case study led presentations, allowing attendees to gain an essential industry update on hot industry topics including:
TRANSLATIONAL APPROACH TO DISCOVERY:
Developing and maintaining a translational strategy – bridging the gap and speeding time to market
PREDICTIVE DISCOVERY TECHNOLOGIES:
Achieving the successful integration of predictive technologies
Biomarkers: determining and measuring the business case for developing and integrating biomarkers
OPTIMISING LEAD GENERATION AND VALIDATION:
Effective utilisation of genomics, proteomics, metabolomics, and HTS/HCS
DEVELOPING NEW APPROACHES TO DISCOVERY:
Employing structural biology and medicinal chemistry methodologies
INTEGRATING CHEM- AND BIO-INFORMATICS:
Achieving interoperability and integrating informatics, chem- and bio-informatics within discovery
STRATEGY: Consolidating the discovery and development process: cutting costs, increasing efficiencies and maximising productivity
PORTFOLIO MANAGEMENT: Strategically managing the discovery portfolio: the business case for emerging technologies and alliances and partnerships
|
|
|
|
|
|
|
|
Organized by:
|
|
Oxford International |
|
|
Invited Speakers:
|
|
· Dr. Catherine Strader, Executive Vice President, Discovery Research, Schering-Plough
· Dr. Joseph Miletich, Senior Vice President, Research & Pre-clinical Development, Amgen
· Dr. Anthony Ford-Hutchinson, Executive Vice President, Worldwide Basic Research, Merck & Co.
· Dr. Gary Peltz, Head, Genetics and Genomics, F. Hoffmann-La Roche
· Dr. Ted Torphy, Vice President, Science & Technology, Johnson & Johnson
· Dr. Scott Shepard, Director, Discovery Scientific Applications Technology, Wyeth
· Dr. Deniz Razon, Director, Alliance Management, Abbott Laboratories
· Dr. Daniel Burns, Vice President, Discovery Genetics, GlaxoSmithKline
· Dr. Teri Loxam, Associate Director, Portfolio Management, Bristol-Myers Squibb
· Dr. Mike Kuranda, Director, Lead Discovery, Millennium Pharmaceuticals
· Dr. Tina Garyantes, Director, Lead Discovery Technologies, Sanofi-Aventis
· Dr. Lynn Rutkowski, Head of Biomarker Development, Wyeth
· Dr. David Friedman, Associate Director, Biomarker Technologies and Head of Proteomics, Vertex Pharmaceuticals
· Dr. Christoph Pittius, Executive Director and Head, Global Discovery Alliances, Boehringer Ingelheim Pharmaceuticals
· Dr. Thomas Bumol, Vice President, Research Technologies, Eli Lilly
· Dr. Abdel Laoui, Head, Cheminformatics, Lead Generation Informatics, Sanofi-Aventis
· Dr. Trevor Mundel, Head, Translational Medicine, Novartis
· Dr. Jonathon Lyon, Head, Molecular Pathology and Toxicology, GlaxoSmithKline
· Dr. Carl Alden, Vice President, Molecular Investigative Toxicology, Millennium Pharmaceuticals Inc
· Dr. Jeffrey Ares, Associate Director, Medicinal Chemistry, Procter & Gamble
· Dr. Bryan Landgraf, Senior Director, Cell & Molecular Biology, UCB Pharma
· Dr. Jack Kloeber, Director, Portfolio Management, Johnson & Johnson
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
31 August
|
|
|
|
|
|
|
|
Registration:
|
|
Please register at www.usdrugdiscoverysummit.com or contact Joanne Taylor at summitmarketing@oxfordint.com or call +44 (0) 870 890 3303
|
|
|
E-mail:
|
|
ddsus06@oxfordint.co.uk
|
|
|
|
|
|
|
|
|